Life Extending Care.
Targeted.
What is Theranostics?
Theranostics combines precise, molecular‑level imaging with targeted therapies to deliver truly personalized cancer care.
By using diagnostic scans to pinpoint tumours and then deploying treatments engineered to seek out those same molecular markers...
Theranostics maximizes effectiveness while sparing healthy tissue.
The Targeted Approach
Our Theranostic protocol combines precision imaging and targeted radiotherapy in
one seamless outpatient procedure.
By injecting a molecular tracer that highlights every prostate‑cancer lesion on high‑resolution PET/SPECT imaging, it is possible to accurately map tumor sites and then deliver therapy directly to those spots—eradicating cancer cells from within while preserving healthy tissue. Administered as a simple 30‑minute outpatient infusion and repeated in cycles, it drives stepwise disease reduction with dramatically fewer side effects.
“When I was diagnosed with cancer, I was offered very few options but when I discovered the options provided by Theranostics and how minimal the side effects were it forever changed my life”
— Bill P, Patient
Pluvicto®. FDA Approved.
The Promise:
On March 28, 2025, the FDA broadened the indication for lutetium Lu 177 vipivotide tetraxetan (Pluvicto®) to include patients with PSMA‑positive metastatic castration‑resistant prostate cancer who have progressed on one ARPI and are appropriate to delay taxane‑based chemotherapy. This decision was driven by the Phase III PSMAfore trial, in which Pluvicto® more than doubled median radiographic progression‑free survival (11.6 months vs. 5.6 months) and cut the risk of progression or death by 59% versus a switch in ARPI. Delivered as a 30‑minute outpatient infusion with predominantly Grade 1–2 side effects, this landmark approval offers patients earlier access to a highly targeted therapy that delays chemotherapy and enhances quality of life.
Benefits of Our Treatment
Cancer Care Designed Around You
Comprehensive Tumor Mapping
A cancer‑seeking tracer “paints” every prostate‑cancer lesion, lighting them up on PET/SPECT so even tiny metastases are detected.
Highly Targeted Therapy
The same tracer is then relabeled with a therapeutic radioisotope, homing in on only cancer cells to deliver radiation “grenades” from within.
Dramatically Fewer Side Effects
Because radiation is confined to tumor cells, healthy tissue is spared—patients report virtually no collateral damage.
Fast, outpatient‑friendly cycles
Each treatment is a simple 30‑minute IV infusion, with many patients seeing an ~80% drop in visible metastases after just one session—and further gains with repeat cycles.
Change You Can See.
Alan H. was diagnosed with stage‑four prostate cancer and flew to Germany for a pioneering theranostics treatment—after just one session, 80% of his metastases were wiped out. Nearly two years on, he has just three small dormant spots remaining, a testament to the treatment’s transformative power.
"It just kept getting better...It just kept erasing the cancer."
Alan H.
Stage‑4 Prostate Cancer Patient
Visit One of Our Treatment Locations.
